Dual-Receptor GH Stimulation for Pulsatile Growth Hormone Research
CJC-1295 / Ipamorelin Blend — Synergistic GH Secretagogue Combination
The CJC-1295 / Ipamorelin blend combines two complementary growth hormone secretagogues in a single formulation. CJC-1295 (a GHRH analogue) stimulates the pituitary to release GH through the GHRH receptor, while Ipamorelin (a ghrelin mimetic) activates GH release through the GHSR-1a receptor. Together, they produce synergistic, pulsatile GH release that closely mimics the body's natural GH secretion pattern.
The blend contains equal parts CJC-1295 (a 30-amino-acid GHRH analogue with DAC technology for extended half-life) and Ipamorelin (a 5-amino-acid selective GHSR-1a agonist). The 1:1 ratio is designed to maximize synergistic GH release through complementary receptor pathways.
CJC-1295 activates GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH synthesis and release. Ipamorelin simultaneously activates GHSR-1a (ghrelin receptor) on the same cells, providing a complementary and synergistic signal. The combination produces GH release significantly greater than either peptide alone, while preserving the natural pulsatile pattern.
The CJC-1295/Ipamorelin blend combines two growth hormone-stimulating peptides that work through different receptors, producing synergistic GH release that closely mimics the body's natural pulsatile GH secretion.
CJC-1295 tells the pituitary to release GH through the GHRH receptor pathway, while Ipamorelin does the same through the ghrelin receptor (GHSR-1a). Using both together produces significantly more GH release than either peptide alone, without cortisol or prolactin elevation.
Growth hormone declines with age, contributing to reduced muscle mass, increased fat, and slower recovery. The CJC-1295/Ipamorelin combination restores youthful GH pulsatility without exogenous GH administration, preserving natural feedback mechanisms.
The CJC-1295/Ipamorelin blend is the gold standard GH secretagogue combination — synergistic dual-receptor activation, pulsatile GH release, and selective action without cortisol or prolactin elevation.
CJC-1295 activates GHRH receptors while Ipamorelin activates GHSR-1a receptors, producing synergistic GH release significantly greater than either peptide alone.
The combination preserves the natural pulsatile pattern of GH release, maintaining GH receptor sensitivity and avoiding tachyphylaxis.
Unlike older GH secretagogues, Ipamorelin does not stimulate cortisol or prolactin release, making the blend highly selective for GH secretion.
Growth Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Components | CJC-1295 (GHRH analogue) + Ipamorelin (GHSR agonist) |
| Blend Ratio | 1:1 (equal parts CJC-1295 and Ipamorelin) |
| Regulatory Status | Research chemicals; no clinical approval |
| Available Sizes | 5mg (2.5mg each), 10mg (5mg each) |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers CJC-1295 / Ipamorelin Blend with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase CJC-1295 / Ipamorelin Blend at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
